Overview

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2024-01-31

Target enrollment:

Participant gender:

Summary

To assess the efficacy and safety of SH-1028 tablets versus Gefitinib, a standard of care epidermal growth factor receptor tyrosine kinase inhibitor, in patients with locally advanced or Metastatic Non Small Cell Lung Cancer

Phase:

Phase 3

Details

Lead Sponsor:

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Treatments:

Gefitinib